60 Participants Needed

Dapansutrile for Heart Attack Recovery

JR
Overseen ByJonathan R Lindner, MD

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a pill called dapansutrile on heart attack patients who received prompt care. The pill aims to reduce inflammation, which can help lower harmful artery plaque and improve heart function.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are using immunosuppressive medications, you may not be eligible to participate.

How is the drug Dapansutrile unique for heart attack recovery?

Dapansutrile is unique because it targets inflammation, which is a key factor in heart attack recovery, by inhibiting a specific protein involved in the inflammatory process. This approach is different from traditional treatments that primarily focus on improving blood flow or reducing heart workload.12345

Are You a Good Fit for This Trial?

This trial is for individuals who have had a type I heart attack and received reperfusion therapy within the last 48 hours. They must have certain levels of artery plaque or thickness to join. People with severe kidney issues, recent strokes, allergies to specific agents, pregnancy, life-threatening complications from their heart attack, certain infections or cancers can't participate.

Inclusion Criteria

I have plaque in my carotid or femoral artery, or my carotid artery wall is thick.
I have had or am scheduled for a procedure to restore blood flow within the last 2 days.
I have had a recent heart attack.

Exclusion Criteria

Pregnancy or breastfeeding
I am currently receiving or recently received treatment for cancer.
I am taking immunosuppressive drugs or have an immune deficiency.
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Dapansutrile
  • Placebo
Trial Overview The study tests if dapansutrile (an inflammasome inhibitor) affects carotid plaque volume over six months compared to a placebo in patients after an urgent heart attack treatment. It also looks at inflammation in plaques and how well small blood vessels in the heart are working.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DapansutrileExperimental Treatment1 Intervention
Subjects randomized to receive oral dapnsutrile
Group II: ControlPlacebo Group1 Intervention
Subjects randomized to receive oral placebo

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Virginia

Lead Sponsor

Trials
802
Recruited
1,342,000+

Citations

Protective Effects of Danlou Tablet () against Murine Myocardial Ischemia and Reperfusion Injury In Vivo. [2018]
Efficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris. [2019]
[Results of a trial of a coronary therapeutic agent, Adalat (author's transl)]. [2013]
Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study. [2023]
Usefulness of PY 108-068, a new calcium channel blocker, for angina pectoris. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security